| Title: |
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials |
| Authors: |
Vale, Claire, Godolphin, Peter J, Fisher, David, Horby, Peter W, Kosiborod, Mikhail N, Hochman, Judith S, Webster, Katie, Higgins, Julian P T, Althouse, Andrew D, Berwanger, Otavio, Furtado, Remo H M, Gasparyan, Samvel B, Haynes, Richard, Koch, Gary G, Landray, Martin, Leifer, Eric, Marshall, John, Murthy, Srinivas, Neal, Matthew D, Staplin, Natalie, Diaz, Janet, Sterne, Jonathan A C, Shankar-Hari, Manu |
| Source: |
The Lancet Diabetes & Endocrinology; October 2024, Vol. 12 Issue: 10 p735-747, 13p |
| Abstract: |
Sodium–glucose co-transporter-2 (SGLT2) inhibitors have been proposed as a potential treatment for adults hospitalised with COVID-19, due to their potential anti-inflammatory and endothelial protective effects. Published evidence from randomised control trials (RCTs) does not provide evidence of benefit. We aimed to estimate the effect of oral administration of SGLT2 inhibitors compared with usual care or placebo in adults hospitalised with COVID-19. |
| Database: |
Supplemental Index |
